AndroGel Compounding Legal Status: FDA Rules, 503B Outsourcing, and What Patients Need to Know

FDA Approval Timeline for AndroGel

The FDA approved AndroGel (testosterone gel 1%) on February 28, 2000 under NDA 021015 for testosterone replacement in adult males with conditions associated with deficiency or absence of endogenous testosterone 1. This made it the first transdermal testosterone gel on the U.S. market.

Unimed Pharmaceuticals developed the original formulation. Solvay Pharmaceuticals acquired Unimed, and AbbVie later absorbed Solvay's portfolio. The 1.62% concentration (NDA 022309) followed in April 2011, offering a lower-volume pump application with comparable pharmacokinetics 2. Both strengths remain listed as active in the FDA Orange Book.

Generic versions of testosterone gel 1% entered the market in 2015 after Perrigo and Teva received ANDA approvals. The generics are AB-rated to AndroGel, meaning the FDA considers them therapeutically equivalent. Prices dropped substantially. A 30-day supply of brand AndroGel 1.62% still carries a wholesale acquisition cost above $600, while generic testosterone gel 1% ranges from $50 to $150 depending on pharmacy and quantity 3.

This price gap is one reason compounded testosterone gel has attracted patient interest. But whether compounding is legally permissible depends on specific federal and state pharmacy law.

The Legal Framework for Compounding Testosterone Gel

Compounded testosterone gel is legal. The question is under which pathway.

The Drug Quality and Security Act (DQSA) of 2013 established two distinct compounding tracks under the Federal Food, Drug, and Cosmetic Act (FD&C Act) 4. Section 503A governs traditional pharmacy compounding, while Section 503B created a new category of "outsourcing facilities" subject to FDA oversight.

Under 503A, a licensed pharmacist may compound testosterone gel for an individual patient based on a valid prescription from a licensed prescriber. The pharmacist must comply with United States Pharmacopeia (USP) standards, and the compounded product cannot be an essentially a copy of a commercially available drug unless the prescriber documents a clinical difference (such as a specific concentration, an allergen-free base, or a combination not available commercially) 5.

Under 503B, an outsourcing facility registered with the FDA may compound testosterone gel in larger quantities without patient-specific prescriptions. These facilities face current Good Manufacturing Practice (cGMP) requirements and FDA inspections. They must report adverse events. The trade-off is that 503B facilities gain the ability to distribute compounded products to healthcare facilities and providers for "office use" without individual prescriptions 4.

One wrinkle: the FDA maintains a list of drugs that may be compounded by 503B facilities from bulk drug substances. Testosterone appears on the FDA's list of bulk drug substances for which there is a clinical need 6. This listing supports its availability through outsourcing facilities, though facilities must still demonstrate compliance with all other 503B requirements.

Does the "Essentially a Copy" Rule Block Compounded Testosterone Gel?

Not automatically. The restriction is narrower than many pharmacists assume.

Section 503A prohibits compounding a product that is "essentially a copy" of a commercially available drug. A compounded testosterone gel at the same concentration (1% or 1.62%) in a similar vehicle could face scrutiny. However, the FDA has acknowledged that clinical differences, including alternative concentrations, different inactive ingredients to avoid patient allergies, or combination formulations, can distinguish a compounded product from its commercial counterpart 5.

In practice, many compounding pharmacies prepare testosterone gel at custom concentrations (2%, 5%, 10%, or even 20%) that do not match any FDA-approved product. A prescriber who documents the clinical rationale for a non-standard concentration, a hypoallergenic base, or a combination with progesterone or DHEA provides the legal foundation for 503A compounding. The Endocrine Society's 2018 guideline on testosterone therapy notes that individualized dosing to achieve target serum testosterone of 450 to 600 ng/dL may require formulations outside the commercial range 7.

State pharmacy boards add another layer of regulation. Some states, including Missouri and Texas, have enacted their own compounding rules that are more restrictive than federal law. Others, like Florida, have relatively permissive frameworks. Prescribers and patients should verify compliance with their state's board of pharmacy before assuming a compounded testosterone gel is permitted.

DEA Scheduling and Controlled Substance Rules

Testosterone is a Schedule III controlled substance under the Controlled Substances Act 8. This classification applies equally to branded, generic, and compounded forms.

Prescribers must hold a valid DEA registration. Pharmacies (including compounding pharmacies and 503B outsourcing facilities) must maintain Schedule III inventory records, report suspicious orders, and comply with DEA auditing requirements. Prescriptions for testosterone, whether for branded AndroGel or a compounded gel, require the prescriber's DEA number.

Online telehealth prescribing of testosterone has faced additional scrutiny since 2023. The DEA's proposed rule on the Ryan Haight Act's special registration for telemedicine prescribing of controlled substances has gone through multiple comment periods 9. As of early 2026, the DEA requires an in-person evaluation or a telemedicine encounter that meets the Public Health Emergency exemption criteria before a Schedule III prescription can be issued across state lines. Clinics offering compounded testosterone via telemedicine must manage both DEA and state medical board requirements.

What the AndroGel Label Requires

The AndroGel label carries two major safety communications that also apply to compounding discussions.

Boxed warning on secondary exposure. In 2009, the FDA mandated a boxed warning after post-market reports of virilization in children who had skin contact with adults using testosterone gel. Symptoms included enlarged genitalia, advanced bone age, aggressive behavior, and premature pubic hair development 10. The label instructs patients to wash hands immediately after application, cover the application site with clothing, and wash the site before skin-to-skin contact with women or children.

Compounded testosterone gels are not required to carry identical labeling to AndroGel. However, compounding pharmacists operating under 503A must provide adequate directions for use. The FDA has issued warning letters to compounders whose labels lacked secondary-transfer precautions 10. "A compounded product does not escape the obligation to ensure patient safety simply because it lacks an NDA," stated Janet Woodcock, then-director of the FDA's Center for Drug Evaluation and Research, in a 2019 advisory to compounding stakeholders.

Cardiovascular risk warning. In March 2015, the FDA required all testosterone product labels to include a warning about possible increased risk of heart attack and stroke 8. This decision followed a review of two observational studies and a clinical trial (TTrials) that raised signal concerns, though the evidence was mixed.

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, found that testosterone gel (AndroGel 1%) improved sexual function, physical function, and bone mineral density over 12 months 11. The TTrials also identified a statistically significant increase in coronary artery plaque volume by coronary CT angiography in the testosterone group, though the clinical significance of that finding remained debated.

Cardiovascular Safety: The TRAVERSE Trial Settled the Primary Question

For years, the cardiovascular question lingered. TRAVERSE answered it.

The TRAVERSE trial (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men), published in the New England Journal of Medicine in 2023, randomized 5,246 men aged 45 to 80 with hypogonadism and pre-existing or high risk of cardiovascular disease to transdermal testosterone 1.62% gel or placebo 12. The primary outcome was first occurrence of a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke.

At a mean follow-up of 33 months, the primary composite occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (hazard ratio 0.96 to 95% CI 0.78 to 1.17) 12. Testosterone was non-inferior to placebo for major adverse cardiovascular events. This was the largest and longest randomized trial of testosterone therapy ever conducted.

"TRAVERSE provides the reassurance that the field needed," said Dr. Shalender Bhasin, the trial's principal investigator and professor of medicine at Harvard Medical School. "The cardiovascular risk signal from earlier observational studies was not confirmed in a rigorous, adequately powered trial."

The FDA has not yet removed or softened the 2015 cardiovascular warning on testosterone labels based on TRAVERSE data, though an advisory committee review is anticipated. For compounded testosterone gel, the practical implication is that prescribers can cite TRAVERSE when counseling patients, but the current label language still applies to all commercially available testosterone products.

Post-Market Surveillance and Adverse Event Reporting

A key difference between branded/generic and compounded testosterone gel is adverse event reporting infrastructure.

AbbVie (for AndroGel) and generic manufacturers must submit periodic safety update reports (PSURs) and individual case safety reports (ICSRs) to the FDA through the MedWatch system. The FDA Sentinel System, an active surveillance network drawing on claims data from over 100 million patients, also monitors testosterone use for safety signals 13.

Compounding pharmacies under 503A have no mandatory FDA adverse event reporting obligation. Section 503B outsourcing facilities do have a reporting obligation, which mirrors the requirements for conventional manufacturers. This gap in 503A surveillance means that safety signals from compounded testosterone gel may be underdetected. The FDA flagged this concern in its 2020 report to Congress on the state of pharmacy compounding 5.

Between 2012 and 2022, the FDA received 30 reports of contamination or superpotency events involving compounded hormone products, including testosterone 14. Not all events resulted in patient harm, but several led to warning letters, consent decrees, or facility closures. Patients using compounded testosterone should understand that the lack of FDA premarket review means the burden of quality assurance rests on the compounding pharmacy's internal processes and state board inspections.

State-Level Variation in Compounding Regulation

Fifty states, fifty regulatory environments. That is not an exaggeration.

The National Association of Boards of Pharmacy (NABP) has published model rules for sterile and non-sterile compounding, but adoption varies. For testosterone gel (a non-sterile preparation), key state-level variables include: whether a face-to-face prescriber-patient relationship is required before a compounding prescription can be filled, whether the state permits 503B facilities to ship into the state without additional licensure, and whether the state imposes concentration limits on compounded controlled substances 15.

California's Board of Pharmacy requires compounding pharmacies to hold a separate compounding license and undergo periodic inspections specific to compounding operations. New York restricts the volume of compounded controlled substances a pharmacy can prepare without triggering additional DEA reporting. Florida, by contrast, permits 503B outsourcing facilities to distribute broadly within the state and has become a hub for compounded hormone therapy production.

Patients who receive compounded testosterone gel shipped across state lines should confirm that both the sending and receiving states permit the transaction. Interstate shipment of compounded controlled substances adds DEA transport requirements on top of state pharmacy board rules.

Who Should Consider Compounded Testosterone Gel

Not every patient needs a compounded product. The decision rests on clinical specifics.

Compounded testosterone gel may be appropriate when: the patient requires a concentration not commercially available (e.g., 5% or 10%), the patient has a documented allergy to an inactive ingredient in AndroGel or its generics (such as ethanol sensitivity or carbomer-related contact dermatitis), the prescriber wants to combine testosterone with another active ingredient in a single preparation, or cost is a barrier and the compounded version is less expensive than generic alternatives.

The Endocrine Society guideline recommends against testosterone therapy in men who have not been confirmed as hypogonadal by two morning serum testosterone levels below 300 ng/dL 7. This threshold applies regardless of whether the patient uses branded, generic, or compounded testosterone gel. Prescribers should also screen for contraindications including polycythemia (hematocrit above 54%), untreated obstructive sleep apnea, uncontrolled heart failure, and desire for fertility within 12 months.

Monitoring on compounded testosterone gel should mirror the labeled recommendations for AndroGel: serum testosterone at 2 to 4 weeks after initiation, then every 6 to 12 months, along with hematocrit, PSA, and lipid panels 7. The gel's transdermal delivery provides steady-state levels without the peaks and troughs associated with intramuscular injections, a pharmacokinetic advantage that applies to both commercial and compounded formulations.